Volume 16, Issue 3 (11-2002)                   Med J Islam Repub Iran 2002 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
FOROOTAN PISHBUARY H, MIRMOMEN S, ALAMDARY S, GHOFRANI H, FARAHVASH M, Y OSSEFI MASHHOOR M et al . THE EFFICACY AND SA FETY OF INTERFERON ALFA FOR THE TREATMENT OF CHRONIC HEPATITIS B INFECTED SUBJECTS IN IRAN. Med J Islam Repub Iran 2002; 16 (3) :139-134
URL: http://mjiri.iums.ac.ir/article-1-1637-en.html
THE EFFICACY AND SA FETY OF INTERFERON ALFA FOR THE TREATMENT OF CHRONIC HEPATITIS B INFECTED SUBJECTS IN IRAN
H FOROOTAN PISHBUARY , S MIRMOMEN , S ALAMDARY , H GHOFRANI , MJ FARAHVASH , M Y OSSEFI MASHHOOR , F GHANAIE
From the Digestive Disease Research Unit of Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, I.R. Iran. , emamddrc@mirmomen.com
Abstract:   (4505 Views)
This preliminary study was designed to evaluate the effects of Heberon Alfa for the treatment of chronic hepatitis B infected subjects in Iran. A single center, open label, single treatment prospective study of Interferon Alfa (Heberon Alfa), 5 million units every other day for a period of 4 months, was performed between 1996 to 1998. A total number of 30 patients with histologically documented chronic hepatitis and positive serum HBsAg were included in the study. Serum ALT of all patients was greater than 1.5 times normal before start of therapy. Effect of therapy on aminotransferase activity and HBsAg, HBeAg seroconversion was monitored and all the patients underwent a second liver biopsy at the end of the study period. Mean age of patients was 35.5 ± 12 (17 to 60 years old) and 73% of patients were male. Most patients experienced adverse effects, but none warranted stopping the treatment. No serious or unexpected adverse event was reported during the study period. Thrombocytopenia was recorded in 2 patients. Liver biopsy showed a decrease in hepatic inflammation in 53.5% of patients, no change in 36.70/0 and increase in hepatic inflammation in 100/0 of patients after the treatment. Serum ALT returned to normal in 18 patients (60%), decreased in 7 patients (23.3%) and didn't change in 5 patients (16.7%). There was a strong correlation between serum ALT normalization and histological improvement. HBsAg became negative in 5 patients (16.6%). 10 patients had positive HBeAg prior to therapy, which became negative in 4 of then1 (40%) by the end of the study. The current study confirms the result of other clinical trials and indicates that Heberon Alfa is a safe and effective drug for the treatment of chronic hepatitis B infected subjects with histologically documented chronic hepatitis.
Keywords: Interferon, chronic hepatitis B, Heberon
Full-Text [PDF 476 kb]   (1610 Downloads)    
Type of Study: Original Research | Subject: Internal Medicine & Gastroenterology
Add your comments about this article : Your username or Email:
CAPTCHA
Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.